Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV CAR-T /TCR-T Cells in Recurrent / Refractory EBV Positive Nasopharyngeal Carcinoma
NCT05587543Phase 1Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2022
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EBV-specific CAR-T cells and anti-EBV autologous TCR-T cell injection in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Fudan University. Primary endpoints: Dose Limiting Toxicities at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
EBV-specific CAR-T cellsanti-EBV autologous TCR-T cell injection
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05587543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587543.